Lannett Gets FDA Approval For Its Neomycin Sulfate Tablets

Lannett Company, Inc.

revealed Monday that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Neomycin Sulfate Tablets USP, 500 mg, the therapeutic equivalent to the reference listed drug, Neomycin Sulfate Tablets USP, 500 mg, of Teva Pharmaceuticals USA, Inc. Lannett said that based IMS, total sales of Neomycin Sulfate Tablets USP, 500 mg, at Average Wholesale Price (AWP) were approximately $3 million in the United States in the last year. The company's CEO, Arthur Bedrosian, commented, "The approval for Neomycin Sulfate Tablets expands our portfolio of anti-infective and antibiotic products and represents our fifth approval in 2016. We expect to commence marketing the product in the next several months, adding to our positive momentum as we enter the coming fiscal year." On Friday, shares of the company shed 3.69 percent.